News & Media

Press release
A joint patent application for MALT1 inhibitors published

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that a joint patent application for MALT1 inhibitors submitted together with...

Read more
Press release
Medivir to present at the ProHearings shared Capital Markets Day

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the ProHearings shared Capital Markets...

Read more
Press release
Medivir invites to a conference call on new clinical data and further studies with MIV-818

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) invites to a conference call on the supporting clinical data from the completed...

Read more
Press release
Abstract for MIV-818 phase 1b monotherapy for ESMO Congress published

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that the Abstract entitled “Phase 1 study of the novel prodrug...

Read more
Press release
Medivir to present at the Wainwright Annual Global Investment Conference

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the virtual meeting H.C. Wainwright...

Read more
Press release
Medivir receives regulatory approval from MHRA for phase 1/2a combination study with MIV-818

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that the company has received regulatory approval from the British Medicines...

Read more
Press release
MEDIVIR AB – INTERIM REPORT JANUARY – JUNE 2021

April – June Financial summary for the quarter Net turnover amounted to SEK 0.9 (4.0) million. The loss before interest, tax,...

Read more
Press release
Medivir strengthens the business development potential of remetinostat through renegotiated multi-party agreement

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announced today that Medivir AB (“Medivir” or “the Company”) together with the originators...

Read more
Press release
Positive data from the remetinostat phase II study in basal cell carcinoma published in Clinical Cancer Research

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR) announced today that positive data from the investigator-initiated study evaluating the effects of remetinostat...

Read more
Press release
Data from Medivir’s MIV-818 phase 1b study to be presented at the ESMO Congress

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that an e-poster entitled “Phase 1 study of the novel prodrug...

Read more
Press release
Medivir appoints Malene Jensen as VP Clinical Development

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announced today it has appointed Malene Jensen as Vice President Clinical Development. She...

Read more
Press release
Medivir to present at the Redeye Growth Day

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the virtual meeting Redeye Growth...

Read more